PACS CEO Executes 20 Straight Sales at $43 vs. $59 Target
PACS Group co-founder and CEO Jason Murray has executed 20 consecutive open-market stock sales from August 17 through September 9, 2026, all at prices between $42.35 and $44.85 and reported as made un
PACS CEO Executes 20 Straight Sales at $43 vs. $59 Target
NEW YORK, September 13 —
PACS Group, Inc. (PACS) CEO Jason Murray is simultaneously the architect of a 32-facility Florida acquisition and the seller of 20 consecutive stock blocks from August 17 through September 9, all between $42.35 and $44.85, under a preset trading plan. Analyst consensus targets $59, more than $14 above Murray's exit prices.
- 20 insider sales Aug 17, Sep 9, $42.35, $44.85 range, preset plan; consensus target $59.00
- Most recent quarter: $0.63 EPS actual vs. $0.56 estimate, third consecutive beat; $5.55B TTM revenue, +9.1% YoY
- $378M free cash flow TTM; $3.40B debt against $160M cash; 16.5x forward P/E at $44.76
Preset Plan, Unanswered Gap
Murray's 20-sale sequence is systematic, not episodic. Each transaction fell within a roughly 6% price band, pointing to a preset plan calibrated to current market levels rather than a target price the CEO expects to reach. A preset plan removes the trading-window problem but raises a different one: at what price was that plan designed? The $59 analyst consensus implies real upside, but running a DCF calculator against PACS's free cash flow and debt load may tell a different story. Insiders hold 69.1% of shares; when the largest holder sells methodically, that implicit message carries weight.
Growth Numbers, Leverage Consequence
PACS Group operates skilled nursing facilities, assisted living communities, and independent living properties across the United States, acquiring and leasing healthcare real estate through its subsidiaries. The earnings trajectory moved sharply: a 4.3% miss four quarters ago gave way to three straight beats of 26.4%, 56.5%, and 12.5%, against $5.55 billion in trailing revenue growing 9.1%. Free cash flow of $378 million supports the acquisition push, including the Florida 32-facility deal. The balance sheet defines the risk: $3.40 billion in debt against $160 million cash leaves the company exposed to any softness in occupancy or government reimbursement, conditions that have historically reset valuations across this sector.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| PACS | $7.1B | 16.5x | +329.1% |
| BTSG | $11.6B | 25.8x | +116.1% |
| SEZL | $4.0B | 17.9x | +32.0% |
| ULS | $14.4B | 27.4x | +5.5% |
| LOAR | $6.2B | 41.1x | -14.4% |
| CGON | $6.4B | n/a | +109.1% |
Three Benchmarks Before Year-End
Three data points will close or widen the contradiction. First, whether Murray continues selling past September 9 or modifies his preset plan: a halt points to a deliberate price floor, a continuation confirms distribution. Second, the financial terms of the Florida acquisition, undisclosed so far: 32 new facilities at PACS's 17.3% gross margin need to be accretive on a per-bed basis or they add debt without earnings power. Third, fourth-quarter EPS against consensus: a beat larger than 12.5% would be harder to reconcile with a CEO systematically exiting at $43. Run the free PACS Group, Inc. deep-dive → for current metrics.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
PACS Group co-founder and CEO Jason Murray has executed 20 consecutive open-market stock sales from August 17 through September 9, 2026, all at prices between $42.35 and $44.85 and reported as made under a preset trading plan, while the analyst consensus price target stands at $59 and the company simultaneously announced a 32-facility acquisition in Florida. The same executive who is methodically liquidating at $43 leads a company whose most recent quarter beat analyst EPS estimates by 12.5% and whose cash flow supports an ongoing acquisition campaign.